Comtan Related Published Studies
Well-designed clinical trials related to Comtan (Entacapone)
The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. [2011.01]
Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. [2011.01]
Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine
prodrug L-DOPS. [2011]
Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa. [2010.11]
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. [2010.07]
Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. [2009.05]
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. [2009.03.15]
Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. [2009.02.15]
Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. [2007.11]
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. [2007]
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. [2006.06.27]
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. [2005.05]
Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. [2005.01]
Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. [2005]
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. [2004.10]
Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug. [2004.09]
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. [2004.09]
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome. [2004.06]
Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients. [2004.02]
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. [2003.08]
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. [2003.03]
Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. [2002.10]
The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease. [2002.06]
Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. [2002.05]
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). [2002.04]
COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. [2002.02.26]
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States. [2002]
The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease. [2001.05]
Twelve-month safety of entacapone in patients with Parkinson's disease. [2001.01]
The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease. [2001.01]
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. [2000.05]
Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. [1998.11]
Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. [1998.07]
A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. [1996.08]
Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. [1996.01]
Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. [1996]
COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers. [1996]
The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. [1995.08]
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. [1995.02]
Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. [1994.02]
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. [1993]
Well-designed clinical trials possibly related to Comtan (Entacapone)
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. [2011.10]
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. [2011.06]
Milestones in Parkinson's disease therapeutics. [2011.05]
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease. [2010.12]
Validation of the freezing of gait questionnaire in patients with Parkinson's disease. [2009.04.15]
Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. [2008.01]
Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. [2008]
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. [2005.03.12]
Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. [1998.07]
Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. [1996.04]
Other research related to Comtan (Entacapone)
Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. [2011.12.05]
Immediate Versus Delayed Switch From Levodopa/Carbidopa to Levodopa/Carbidopa/Entacapone: Effects on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-Dose Wearing Off. [2011.11]
The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations. [2011.09.17]
Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED. [2011.02.20]
The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis. [2011.01.01]
Immediate versus delayed switch from levodopa/carbidopa to
levodopa/carbidopa/entacapone: effects on motor function and quality of life in
patients with Parkinson's disease with end-of-dose wearing off. [2011]
Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients. [2010.10]
Entacapone. [2010.08]
Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease. [2010.07]
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study. [2010.03]
Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus. [2010.01.14]
Initiating levodopa/carbidopa therapy with and without entacapone in early
Parkinson disease: the STRIDE-PD study. [2010]
Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis. [2009.12]
Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference. [2009.11.03]
Levodopa/carbidopa/entacapone in Parkinson's disease. [2009.07]
Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis. [2009.06.30]
Development and application of a high-performance liquid chromatographic method for the determination of in vitro drug release of levodopa, carbidopa, and entacapone from a tablet formulation. [2009.03]
Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study. [2009.02]
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. [2009.01.15]
Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study. [2009]
Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient. [2008.12.15]
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. [2008.12.03]
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes. [2008.12]
Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). [2008.11]
Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). [2008.10.31]
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. [2008.10.07]
The effect of entacapone on levodopa rate of absorption and latency to motor response in patients with Parkinson disease. [2008.09]
Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease. [2008.07.30]
Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort. [2008.07]
Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease. [2008.06]
Bimodal administration of entacapone in Parkinson's disease patients improves motor control. [2008.03]
Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease. [2008.03]
Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease. [2008.02.08]
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. [2007.12]
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. [2007.11]
Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off. [2007.08.15]
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. [2007.06.14]
One-year open-label study of entacapone in patients with advanced Parkinson disease. [2007.06]
Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off. [2007.05.21]
Entacapone improves complex movement performance in patients with Parkinson's disease. [2007.05]
Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention. [2007.03]
Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients. [2007.01]
Entacapone Prolongs the Reduction of PLM by Levodopa/Carbidopa in Restless Legs Syndrome. [2007]
Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy. [2006.12]
Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy. [2006.10.16]
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. [2006.10]
The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. [2006.05]
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats. [2006.05]
Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients. [2006.03]
High-performance liquid chromatography method for the quantification of entacapone in human plasma. [2005.09.05]
|
